A5018426062- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Cancer Risks and Factors
- Estrogen and related hormone effects
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Cancer Cells and Metastasis
- Metabolism, Diabetes, and Cancer
- Lung Cancer Treatments and Mutations
- Breast Lesions and Carcinomas
- Lung Cancer Research Studies
- Cancer, Lipids, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Growth Hormone and Insulin-like Growth Factors
- Nutrition and Health in Aging
- Musculoskeletal pain and rehabilitation
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Breast Implant and Reconstruction
- Monoclonal and Polyclonal Antibodies Research
- Circular RNAs in diseases
- Heart Rate Variability and Autonomic Control
The University of Texas MD Anderson Cancer Center
2017-2025
Cancer Center of Hawaii
2023-2025
University of Hawaiʻi at Mānoa
2023-2025
University of Hawaii System
2023-2025
University of Hawaii Cancer Center
2024-2025
Cancer Institute (WIA)
2023
The University of Texas Health Science Center at Houston
2020
University of Antwerp
2020
Institut Paoli-Calmettes
2020
Japanese Foundation For Cancer Research
2019
Inflammatory breast cancer (IBC), the most aggressive subtype, is driven by an immunosuppressive tumor microenvironment (TME). Current treatments for IBC have limited efficacy. In a clinical trial (NCT01036087), anti-EGFR antibody combined with neoadjuvant chemotherapy produced highest pathological complete response rate ever reported in patients having triple-negative receptor status. We determined molecular and immunological mechanisms behind this superior outcome. Using novel humanized...
Abstract Obesity is known to decrease the efficacy of neoadjuvant chemotherapy ( NAC ) against breast cancer; however, relationship between actual body composition and outcomes remains unknown. Therefore, we determined effect on outcomes. A total 172 advanced cancer patients who underwent surgery after were retrospectively analyzed. Body parameters including abdominal circumference AC ), subcutaneous fat area SFA visceral VFA skeletal muscle SMA calculated using computed tomography...
A precise predictive biomarker for TNBC response to immunochemotherapy is urgently needed. We previously established a 27-gene IO signature derived from 101-gene model classifying TNBC. Here we report pilot study assess the performance of in predicting pCR preoperative immunochemotherapy. obtained RNA sequencing data primary tumors 55 patients with TNBC, who received neoadjuvant PD-L1 blocker durvalumab. determined power and accuracy immunomodulatory (IM) subtype identified by model,...
The aim of the present study was to evaluate association between changes in neutrophil-to-lymphocyte ratio and survival rate, as well tumor subtype, recurrent breast cancer. Patients with cancer following surgery were included this study. NLR calculated compared two time points: Pre-treatment recurrence. associations longitudinal change, at recurrence overall (OSrec) evaluated. A total 89 patients increased by 0.59 recurrence, initial treatment (P<0.05). triple negative (TN) type...
We used a novel shape-restricted Cox model to determine the desirable ER expression cutoff predict breast cancer prognoses. Our treats as continuous variable using flexible monotone-shaped regression assess its association with survival outcomes holistically. The study included 3055 patients stage II/III HER2-negative cancer. primary were time recurrence or death (TTR) and overall (OS). identified 10% preferred TTR. finding was confirmed by log-rank test standard that ≥ had TTR benefit over...
Human epidermal growth factor 2 (HER2) is an effective therapeutic target in breast cancer; however, resistance to anti-HER2 agents such as trastuzumab and lapatinib develops. In a preclinical model, HDAC inhibitor epigenetically reversed the of cancer cells showed synergistic efficacy with inhibiting trastuzumab-resistant HER2-positive (HER2+) cancer.A phase 1b, dose escalation study was performed assess maximum tolerated dose, safety/toxicity, clinical explored pharmacodynamic biomarkers...
e15045 Background: Increased cancer cell mitosis in tumor tissue is widely regarded as an indicator of aggressive disease, a predictor shorter survival, and response to specific anthracycline based chemotherapies. Circulating cells (CTCs) are that detach from primary tumors, enter the bloodstream, seed metastatic sites, which patients (pts) with breast (mBC) also predictors poor prognosis reduced therapy response. Furthermore, small preliminary studies have identified subtype mitotic CTCs...
Abstract Background Radium‐223 dichloride (Ra‐223) is a targeted alpha therapy that induces localized cytotoxicity in bone metastases. We evaluated the efficacy and safety of Ra‐223 plus hormonal hormone receptor‐positive (HR+), bone‐dominant metastatic breast cancer. Methods In this single‐center phase II study, 36 patients received (55 kBq/kg intravenously every 4 weeks) up to 6 cycles with endocrine therapy. The primary objective was determine clinical disease control rate at 9 months....
Objectives In order to elucidate the influence of sympathetic nerves on lumbar radiculopathy, we investigated whether sympathectomy attenuated pain behaviour and altered electrical properties dorsal root ganglion (DRG) neurons in a rat model constriction. Methods Sprague-Dawley rats were divided into three experimental groups. constriction group, left L5 spinal nerve was ligated proximal DRG as radiculopathy model. + performed after procedure. control no procedures performed. evaluate relief...
The aim of the present study was to analyze effect subtype and body mass index (BMI) on neo-adjuvant chemotherapy (NAC) postoperative prognosis. Two-hundred forty nine patients who underwent surgery after NAC were included. A multivariate analysis survival used clarify relationship between BMI, subtype, NAC. In logistic regression model, pCR rate had a significant with tumor stage. non-pCR group, more overweight significantly worse disease-free (DFS) compared normal range (Log lank test, p <...
The purpose of this study was to determine the change in overall survival (OS) for patients with de novo metastatic breast cancer (dnMBC) over time. We conducted a retrospective cohort 1981 dnMBC diagnosed between January 1995 and December 2017 at University Texas MD Anderson Cancer Center. OS measured from date diagnosis dnMBC. compared during different time periods: 5-year periods defined according when key agents were approved clinical use. median 3.4 years. 5- 10-year rates improved...
Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR overexpressed up to 76% amplified 24% triple-negative cancers (TNBC). Here, we aimed identify inhibitors that may enhance the anti-tumor activity neratinib for HER2+ cancer TNBC. By conducting a non-biased high-throughput RNA interference screening, identified PI3K/AKT/mTOR MAPK as two potential inhibitory synergistic canonical pathways. We confirmed everolimus (mTOR...
The aim of the present study was to investigate relationships between automated bone scan index (aBSI) and skeletal-related events (SRE) in breast cancer patients with metastasis. A computer-aided software (BONENAVI™) that developed using an Artificial Neural Network (Artificial Network) used for analysis. Forty-five diagnosed metastasis due from April 2005 through March 2013 were retrospectively analyzed. Before after time initial treatment, aBSI, score, hotspot number calculated, these...
Our previous study indicated that a high amount of visceral adipose tissue was associated with poor survival outcomes in patients early breast cancer who received neoadjuvant chemotherapy. However, inconsistency observed the prognostic role body composition treatment outcomes. In present study, we aimed to validate our research by performing comprehensive analysis standardized clinical background. We included 198 stage III underwent chemotherapy between January 2007 and June 2015. The impact...
Abstract Background Previous randomized clinical trials have shown no significant benefit with the addition of anthracyclines to neoadjuvant treatment for HER2-positive breast cancer. However, these studies did not focus on inflammatory cancer (IBC), or a small minority patients trials. The study aims compare pathologic complete response rates and without in IBC. Methods We reviewed diagnosed Stage III IBC who underwent therapy modified radical mastectomy at MD Anderson Cancer Center...
When breast-conserving therapy was introduced at the Cancer Institute Hospital (CIH) in Tokyo 1986, we instituted our own strategy as follows: 1) every effort is to be made for complete tumor resection while avoiding deformity of breast, and 2) radiotherapy (RT) applied only patients with positive surgical margins. This is, turn, clarify group whom postoperative RT can safely spared. Among 9670 operated on primary breast cancer during 16.5 year period from 1986 2002 CIH, there were 2449 who...
Abstract Background There were several reports suggesting α‐adrenoceptor antagonists are effective to treat neuropathic pain. The aims of this study as follows: (1) introduce drug delivery system for dorsal root ganglion ( DRG ) neurons; (2) elucidate the effects in acute, subacute or chronic phase and (3) determine which subtype adrenoceptor was mainly involved. Method We used 130 male Sprague‐Dawley rats. After constriction, rats received three local injections around . administered...